Hi

We are pleased to present secondary data from MindBio's Phase 2A Microdosing Depression Trial completed earlier this year.

Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-week treatment course with MB22001, (a proprietary self titratable form of Lysergic Acid Diethylamide or LSD, designed for safe take-home microdosing).

This includes a 52% reduction in anxiety (HAM-A), and self-reported reductions in stress (35%), anxiety (59%) and depression (40%) using the DASS questionnaire. Participant’s psychological quality of life was improved by 37% as measured by the WHOQOL. 

Previously released data reported improvements in MADRS Score (Montgomery-Asberg Depression Rating Scale) indicating an overall 60% decrease in depressive symptoms at the end of the treatment period and a 53% complete remission from depression.  The Company is currently assessing the durability of the antidepressant response of MB22001 at 1 months and 3 months post treatment cycle. 

The Company looks forward to revealing these highly important antidepressant durability results to the market shortly.

Safety analysis has shown a favourable adverse event profile with a low frequency of adverse events with no serious or severe adverse events recorded. No clinically significant abnormalities were seen in follow up blood tests, electrocardiograms or echocardiograms.

View Slideshow

It's a great next step in developing this new promising treatment for depression and other related conditions.

We thank you for your support and interest in our scientific work.

Click on the link to view a brief slideshow.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true